Measurement of fractional flow reserve (FFR)

Active Ingredient: Regadenoson

Indication for Regadenoson

Population group: only adults (18 years old or older)

Regadenoson is a selective coronary vasodilator for use in adults as a pharmacological stress agent for the measurement of fractional flow reserve (FFR) of a single coronary artery stenosis during invasive coronary angiography, when repeated FFR measurements are not anticipated.

For this indication, competent medicine agencies globally authorize below treatments:

400 ug once

Route of admnistration

Intravenous

Defined daily dose

400 - 400 ug

Dosage regimen

From 400 To 400 ug once every day for 1 day(s)

Detailed description

The recommended dose is a single injection of 400 micrograms regadenoson into a peripheral vein, with no dose adjustment necessary for body weight.

Patients should avoid consumption of any products containing methylxanthines (e.g. caffeine) as well as any medicinal products containing theophylline for at least 12 hours before regadenoson administration.

When possible, dipyridamole should be withheld for at least two days prior to regadenoson administration.

Aminophylline may be used to attenuate severe and/or persistent adverse reactions to regadenoson but should not be used solely for the purpose of terminating a seizure induced by regadenoson.

Regadenoson causes a rapid increase in heart rate. Patients should remain sitting or lying down and be monitored at frequent intervals after the injection until the ECG parameters, heart rate and blood pressure have returned to pre-dose levels.

Repeated use

This product is to be administered no more than twice, no less than10 minutes apart, during any 24 hour period. When administered twice 10 minutes apart in a 24-hour period, full safety data for the second injection of regadenoson are not available.

Dosage considerations

  • Regadenoson should be administered as a rapid 10-second injection into a peripheral vein, using a 22-gauge or larger catheter or needle
  • 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection should be administered immediately after the injection of regadenoson.
  • FFR should be measured as the lowest value of Pd/Pa achieved during steady state hyperemia.

Active ingredient

Regadenoson

Regadenoson is a low affinity agonist (Ki ≈ 1.3 ξM) for the A2A adenosine receptor, with at least 10-fold lower affinity for the A1 adenosine receptor (Ki >16.5 ξM), and very low, if any, affinity for the A2B and A3 adenosine receptors. Activation of the A2A adenosine receptor produces coronary vasodilation and increases coronary blood flow (CBF).

Read more about Regadenoson

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.